Evommune Earnings Call Transcripts
Fiscal Year 2026
-
A new phase IIb trial will evaluate EVO756, an oral MRGPRX2 antagonist, for migraine prevention, aiming to address unmet needs beyond current CGRP therapies. The program leverages strong mechanistic rationale and seeks to disrupt neuroinflammatory cycles in migraine, with top-line data expected in 2027.
-
EVO301 met its primary and secondary endpoints in a phase 2A trial for moderate to severe atopic dermatitis, showing rapid, durable, and statistically significant efficacy with a clean safety profile after just two doses. The drug demonstrated broad anti-inflammatory activity and is advancing to phase 2B with a subcutaneous formulation.
Fiscal Year 2025
-
EVO756 demonstrated robust efficacy and safety in a phase II trial for chronic inducible urticaria, with 30% of patients achieving complete response and 93% showing improvement in key measures at four weeks. Results support further development in CSU and atopic dermatitis.